CloudAV: N-version antivirus in the network cloud
SS'08 Proceedings of the 17th conference on Security symposium
The future of biologically-inspired security: is there anything left to learn?
NSPW '07 Proceedings of the 2007 Workshop on New Security Paradigms
Methodology for a field study of anti-malware software
FC'12 Proceedings of the 16th international conference on Financial Cryptography and Data Security
A clinical study of risk factors related to malware infections
Proceedings of the 2013 ACM SIGSAC conference on Computer & communications security
| Hi-index | 0.00 |
One of the largest challenges faced by purchasers of security products is evaluating their relative merits. While customers can get reliable information on characteristics such as runtime overhead, user interface, and support quality, the actual level of protection provided by different security products is mostly unranked--or, worse yet, ranked using criteria that do not generally reflect their performance in practice. Even though researchers have been working on improving testing methodologies, given the complex interactions of users, uses, evolving threats, and different deployment environments, there are fundamental limitations on the ability of lab-based measurements to determine real world performance. To address these issues, we propose an alternative evaluation method, computer security clinical trials. In this method, security products are deployed in randomly selected subsets of targeted populations and are monitored to determine their performance in normal use. We believe that clinical trials can provide solid evidence of the efficacy of security products, much as they have in the field of medicine.